PharVision Advisers’s Equinix EQIX Stock Holding History

PharVision Advisers’s Portfolio EQIX Stock Details EQIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-549	Closed	-$437K	–	703
2025 Q2	$437K	Buy	+549	New	+$466K	0.63%	12

Other funds holding EQIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's EQIX Position: Q3 2025 in Review

PharVision Advisers sold out of Equinix (EQIX) in Q3 2025, closing a stake of 549 shares — an estimated $437K sold.

PharVision Advisers first reported a position in EQIX in Q2 2025 and held it in 1 quarter. The position peaked at $437K in Q2 2025. 1,179 funds tracked by Wall St. Rank hold EQIX as of Q3 2025.

PharVision Advisers reported no remaining Equinix position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 549 Equinix shares in Q3 2025, an estimated $437K.
PharVision Advisers first reported a position in Equinix in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Equinix position peaked at $437K in Q2 2025.
1,179 funds tracked by Wall St. Rank held Equinix as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.